Showing results (71-80 of 104) with videos related to
Sort By:
Pageof 11
Yonsei Medical Journal|January 26, 2017
Cross-Cultural Aspect of Behavior Assessment System for Children-2, Parent Rating Scale-Child: Standardization in Korean ChildrenJungeun Song, Bennett L Leventhal, Yun Joo Koh, et al.Journal of the American Academy of Child and Adolescent Psychiatry|April 25, 2008
Observational Assessment of Preschool Disruptive Behavior, Part I: reliability of the Disruptive Behavior Diagnostic Observation Schedule (DB-DOS)Lauren S Wakschlag, Carri Hill, Alice S Carter, et al.Journal of the American Academy of Child and Adolescent Psychiatry|November 25, 2015
Depression and Suicidality Outcomes in the Treatment of Early Age Mania StudyJay A Salpekar, Paramjit T Joshi, David A Axelson, et al.Autism Research : Official Journal of the International Society for Autism Research|October 5, 2023
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studiesJoaquin Fuentes, Mara Parellada, Christina Georgoula, et al.Archives of General Psychiatry|July 5, 2006
Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorderDiane E Dickel, Jeremy Veenstra-VanderWeele, Nancy J Cox, et al.Biological Psychiatry|January 24, 2007
Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorderDiane E Dickel, Jeremy Veenstra-VanderWeele, Nancy Chiu Bivens, et al.Journal of the American Academy of Child and Adolescent Psychiatry|November 25, 2015
Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial TreatmentJohn T Walkup, Karen Dineen Wagner, Leslie Miller, et al.Neuron|September 19, 2014
Unraveling the miswired connectome: a developmental perspectiveAdriana Di Martino, Damien A Fair, Clare Kelly, et al.Child Psychiatry and Human Development|March 16, 2022
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline CharacteristicsChristina Georgoula, Maite Ferrin, Bozena Pietraszczyk-Kedziora, et al.Biological Psychiatry|September 27, 2016
Data-Driven Phenotypic Categorization for Neurobiological Analyses: Beyond DSM-5 LabelsNicholas T Van Dam, David O'Connor, Enitan T Marcelle, et al.Pageof 11